Sort by regulatory tier before anything else. A short list of peptide and peptide-adjacent drugs holds FDA approval for defined male-health conditions. A second tier is compounded from approved molecules and is not itself an approved product. A third tier, the one advertised hardest to men, has no approval and no human outcome data supporting the marketed claims.
Tier one: approved products, and the indication each one carries
Approval is specific. A drug is approved for a population and a condition, not for a goal like recovery or vitality, and the indication is the part most listicles drop.
Testosterone products including AndroGel, Depo-Testosterone and Xyosted are approved as replacement therapy in men with primary or hypogonadotropic hypogonadism, meaning testicular failure or a hypothalamic-pituitary problem. FDA states plainly that none of the approved testosterone products are approved for men with low readings and no associated medical condition. Following review of the TRAVERSE cardiovascular outcomes trial and other data, FDA requested prescribing information updates in June 2026 that removed the limitation of use covering age-related hypogonadism and revised the prostate cancer and benign prostatic hyperplasia safety language. Some marketed labels still carry the older wording, so the label in front of you may lag.
Bremelanotide, sold as Vyleesi, is genuinely approved and constantly misdescribed. Its indication is acquired, generalized hypoactive sexual desire disorder in premenopausal women, and the label states in its limitations of use that it is not indicated in men. It was studied in men with erectile dysfunction, including a randomized trial in sildenafil non-responders, but that program produced no male indication.
Tesamorelin, sold as Egrifta SV and Egrifta WR, is approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. The label adds that it is not indicated for weight loss management because its effect on body weight is neutral. The approved metabolic peptides, semaglutide and tirzepatide, carry their own weight and cardiometabolic indications, and tirzepatide also covers moderate to severe obstructive sleep apnea in adults with obesity.
For the approved end of that list, the same medicines are sold through named telehealth channels a buyer can compare on documentation rather than promises. Ro, Hims and Hers, and Henry Meds route prescriptions through their own pharmacies, LillyDirect connects patients to a manufacturer’s supply, and a provider such as HealthRX states which conditions its peptide therapy is indicated for. Reading those disclosures next to one another tells a buyer more than any single marketing headline.
Tier two and tier three, side by side
| Compound | Regulatory status | Evidence class |
|---|---|---|
| Testosterone (gel, patch, injection, oral) | FDA-approved for male hypogonadism tied to an identified condition | Randomized outcome data, including a cardiovascular safety trial in more than 5,200 men |
| Bremelanotide (Vyleesi) | FDA-approved for premenopausal women with HSDD; label says not indicated in men | Two randomized phase 3 trials in women; earlier randomized work in men did not lead to approval |
| Tesamorelin (Egrifta) | FDA-approved for HIV-associated lipodystrophy only | Randomized placebo-controlled trial in that population |
| Semaglutide, tirzepatide | FDA-approved for weight and metabolic indications | Large randomized trials, separately run |
| Compounded versions of the above | Not FDA-approved products; dispensed against a prescription | Evidence attaches to the molecule, not to the preparation |
| Ipamorelin, GHRP-2, GHRP-6, ibutamoren (MK-677) | Unapproved; all four sit in FDA category 2 of nominated bulk substances | MK-677 raised growth hormone, IGF-1 and fat-free mass in older adults over two years without improving strength or function |
| BPC-157, TB-500, CJC-1295, MOTS-C | Unapproved; nominated for compounding use, then withdrawn from FDA’s list | CJC-1295 has published pharmacodynamic data only. The others have no human outcome trials for the marketed uses |
| Follistatin, IGF-1 LR3 | Unapproved, sold through research-chemical channels | No controlled human trials for muscle or anti-aging claims in healthy men |
Rank the evidence, not the mechanism story
Nearly everything in tier three is marketed through growth hormone. That pathway has been tested directly, which makes the claims checkable. A systematic review of growth hormone in healthy older adults found a small gain in lean mass and a small loss of fat with no improvement in strength or other clinically meaningful outcomes, alongside more adverse events. A second systematic review, this one on athletic performance, found the same pattern: lean mass rose, strength and exercise capacity did not.
That result matters more than any individual secretagogue trial, because raising growth hormone is the whole premise of ipamorelin, CJC-1295, GHRP-2 and MK-677. If maximizing the hormone itself does not deliver strength or performance, a compound that nudges it upward has a hard case to make.
The item most checklists skip
Symptoms men bring to this market, low drive, fatigue, softening body composition, poor recovery, are rarely traced to a peptide deficiency. Obesity lowers measured testosterone through well-described mechanisms and weight loss raises it. Obstructive sleep apnea is associated with lower total testosterone in meta-analysis. One week of sleep restriction dropped daytime testosterone in young healthy men by a measurable margin. Erectile dysfunction travels with cardiometabolic risk closely enough that it functions as an early signal worth investigating rather than masking.
An analysis of men evaluated for erectile dysfunction found that direct-to-consumer prescription platforms missed pathology that a standard office workup identified. A checklist that begins with product selection has already skipped the step with the highest yield.
Only now compare providers
With tier and diagnosis settled, provider questions get narrow. Which clinician holds a license in the patient’s state, what was reviewed before the prescription, which pharmacy fills it and under which section of the compounding law, what monitoring is ordered, and what twelve months costs in total. Direct-to-consumer platforms such as Hims and Hers and Ro, men’s clinic networks such as Defy Medical and Marek Health, and physician-supervised compounding services including FormBlends answer those questions differently and sit under different regulators, so a price comparison across them is only meaningful once the tier is matched.
Two findings that should end a comparison early
The first is a seller that cites rodent or cell-culture work without saying so. The second is a seller that will not name the compounding pharmacy. Testosterone and growth hormone secretagogues are also prohibited in tested sport under the World Anti-Doping Code.
Frequently asked questions
Is PT-141 approved for men?
No. Bremelanotide is approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women, and the prescribing information states in its limitations of use that it is not indicated in men. Randomized work in men with erectile dysfunction was published but did not result in a male indication.
Does a compounded version carry the same evidence as the approved drug?
The molecule keeps its evidence. The preparation does not inherit approval. Compounded drugs are not reviewed by FDA for safety, effectiveness or quality before dispensing, so the pharmacy’s identity and oversight become the variables a buyer can still check.
Why does FDA list BPC-157 and TB-500 if they are unapproved?
Because both were nominated as bulk substances for compounding use and then withdrawn from that list. FDA published safety concerns for each, including immunogenicity risk by certain routes and difficulty characterizing peptide impurities. Listing records a concern, not an endorsement or an approval.
What is the single most useful question on this checklist?
Which condition is being treated and how it was established. Approved products exist for hypogonadism, HIV-associated lipodystrophy and obesity, and each requires a diagnosis first. Without one, the comparison is between unapproved products for a problem nobody has defined.
Do FDA category 2 and withdrawn nomination mean the same thing?
No. Category 2 substances, including ipamorelin acetate, GHRP-2, GHRP-6 and ibutamoren mesylate, were evaluated and flagged as presenting significant safety risks in compounding. Withdrawn nominations were pulled before that process concluded. Neither route makes a substance an approved drug.
